×

Vericel to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will present at the following investor conferences in late September and early October:

  • Ladenburg Thalmann 2015 Healthcare Conference at the Sofitel Hotel in New York on Tuesday, September 29; Vericel's president and CEO Nick Colangelo will present a corporate update at 10:00 a.m. EDT. A live webcast of the presentation will be accessible through the news and events section of the company's website or can be accessed here: http://wsw.com/webcast/ladenburg/vcel
  • The Stem Cell Meeting on the Mesa at the Estancia La Jolla Hotel in La Jolla, CA on Wednesday October 7; Vericel's CSO Ross Tubo, Ph.D., will present a corporate update at 5:45 p.m. PDT. A live webcast of the presentation will be accessible through the news and events section of the company's website or can be accessed here: http://stemcellmeetingonthemesa.com/webcast/

About Vericel Corporation

Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.

CONTACT: Chad Rubin The Trout Group crubin@troutgroup.com (646) 378-2947 or Lee Stern The Trout Group lstern@troutgroup.com (646) 378-2922

Source:Vericel Corporation